Kamil Andrzej Wiązania
Research Subjects
Kamil Andrzej Wiązania has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Rafał Wilczyński
Independent Researcher
5 shared publications - Szymon Wróbel
Murcki Hospital, ul. Alfreda Sokołowskiego 2, 40-749 Katowice, Poland
4 shared publications - Hanna Ludwisiak
Wroclaw Medical University
3 shared publications - Julia Owsik
Wroclaw Medical University
3 shared publications - Maja Maria Porażko
University Clinical Hospital in Opole, Poland
3 shared publications - Małgorzata Dorożalska
Wroclaw Medical University
3 shared publications
Latest Publications
- Open Access
- 28 September 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 5 (3(51))
COMPLICATIONS FOLLOWING AESTHETIC PROCEDURES WITH THE USE OF DERMAL FILLERS- IDENTIFICATION, SEVERITY, CLINICAL MANAGEMENT, AND REDUCING THE RISK - A NARRATIVE REVIEW
Dermal filler procedures have gained widespread popularity in aesthetic medicine due to their accessibility, relatively low cost, and minimal recovery time. However, with increased demand, reports on complications and adverse reactions have also risen. They range from mild, self-limiting cases to rare, severe, and potentially irreversible outcomes. This article reviews the various types of dermal fillers, their mechanisms of action, and details the spectrum of complications—including local site reactions, complications of aesthetic character, infectious, immune-mediated, and vascular events—while highlighting the importance of correct technique, patient selection, and the constant need for ongoing clinician education. The need for evidence-based protocols and clear guidelines is emphasized to enhance patient safety and optimize outcomes in filler-based aesthetic procedures.
- 28 September 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 5 (3(51))
Open AccessCOMPLICATIONS FOLLOWING AESTHETIC PROCEDURES WITH THE USE OF DERMAL FILLERS- IDENTIFICATION, SEVERITY, CLINICAL MANAGEMENT, AND REDUCING THE RISK - A NARRATIVE REVIEW
Dermal filler procedures have gained widespread popularity in aesthetic medicine due to their accessibility, relatively low cost, and minimal recovery time. However, with increased demand, reports on complications and adverse reactions have also risen. They range from mild, self-limiting cases to rare, severe, and potentially irreversible outcomes. This article reviews the various types of dermal fillers, their mechanisms of action, and details the spectrum of complications—including local site reactions, complications of aesthetic character, infectious, immune-mediated, and vascular events—while highlighting the importance of correct technique, patient selection, and the constant need for ongoing clinician education. The need for evidence-based protocols and clear guidelines is emphasized to enhance patient safety and optimize outcomes in filler-based aesthetic procedures.
- Open Access
- 16 September 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 5 (3(51))
CURRENT BIOLOGIC THERAPIES FOR MODERATE-TO-SEVERE HIDRADENITIS SUPPURATIVA: A NARRATIVE REVIEW OF APPROVED TREATMENTS AND CLINICAL IMPLICATIONS
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease characterized by recurrent painful nodules, abscesses, and sinus tracts, resulting in substantial impairment of quality of life. Advances in the understanding of HS immunopathogenesis have led to the development of biologic therapies targeting key inflammatory pathways, particularly TNF-α and IL-17. To summarize current evidence regarding approved biologic therapies for moderate-to-severe HS, focusing on their mechanisms of action, efficacy, safety, and clinical applicability. A narrative literature review was conducted using the PubMed/MEDLINE database. Studies published between January 2016 and June 2026 were screened using the terms “hidradenitis suppurativa”, “adalimumab”, “secukinumab”, “bimekizumab”, and names of pivotal clinical trials. Randomized controlled trials, extension studies, real-world evidence reports, and high-quality reviews were included. Data were qualitatively synthesized. Adalimumab, the first approved biologic for HS, demonstrated significant efficacy in the phase III PIONEER I and II trials, with sustained long-term benefits. Secukinumab showed superior clinical response rates compared with placebo in the phase III SUNSHINE and SUNRISE studies. Bimekizumab demonstrated promising efficacy in both phase II and phase III BE HEARD trials, improving disease activity, pain, and quality of life. Overall, biologic therapies targeting TNF-α and IL-17 pathways consistently improved clinical outcomes in patients with moderate-to-severe HS. Adalimumab remains the established first-line biologic agent, while secukinumab and bimekizumab provide effective alternatives for patients with poor response to TNF-α inhibition. Despite encouraging efficacy and safety data, complete disease remission remains difficult to achieve, highlighting the need for further therapeutic advances.
- 16 September 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 5 (3(51))
Open AccessCURRENT BIOLOGIC THERAPIES FOR MODERATE-TO-SEVERE HIDRADENITIS SUPPURATIVA: A NARRATIVE REVIEW OF APPROVED TREATMENTS AND CLINICAL IMPLICATIONS
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease characterized by recurrent painful nodules, abscesses, and sinus tracts, resulting in substantial impairment of quality of life. Advances in the understanding of HS immunopathogenesis have led to the development of biologic therapies targeting key inflammatory pathways, particularly TNF-α and IL-17. To summarize current evidence regarding approved biologic therapies for moderate-to-severe HS, focusing on their mechanisms of action, efficacy, safety, and clinical applicability. A narrative literature review was conducted using the PubMed/MEDLINE database. Studies published between January 2016 and June 2026 were screened using the terms “hidradenitis suppurativa”, “adalimumab”, “secukinumab”, “bimekizumab”, and names of pivotal clinical trials. Randomized controlled trials, extension studies, real-world evidence reports, and high-quality reviews were included. Data were qualitatively synthesized. Adalimumab, the first approved biologic for HS, demonstrated significant efficacy in the phase III PIONEER I and II trials, with sustained long-term benefits. Secukinumab showed superior clinical response rates compared with placebo in the phase III SUNSHINE and SUNRISE studies. Bimekizumab demonstrated promising efficacy in both phase II and phase III BE HEARD trials, improving disease activity, pain, and quality of life. Overall, biologic therapies targeting TNF-α and IL-17 pathways consistently improved clinical outcomes in patients with moderate-to-severe HS. Adalimumab remains the established first-line biologic agent, while secukinumab and bimekizumab provide effective alternatives for patients with poor response to TNF-α inhibition. Despite encouraging efficacy and safety data, complete disease remission remains difficult to achieve, highlighting the need for further therapeutic advances.
- Open Access
- 8 July 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 61, 73300
Impact of Telehealth on Chronic Disease Control: A Narrative Review
Background. With the continuous development of new technologies, especially digital technologies, the possibilities provided by telehealth continue to increase. Research shows that the use of telehealth tools can be successfully used for managing patients with chronic conditions. Aim. As the number of chronic conditions within the world’s population rises, their effect becomes evident in terms of lowering patients’ quality of life and life expectancy. Telehealth can be an effective solution to this growing problem. This review is intended to examine the state-of-the-art studies in relation to the effect of telehealth on chronic disorder management, focusing mainly on clinical outcomes, quality of life, and healthcare costs. Material and methods. We reviewed the available scientific literature in databases such as PubMed, Scopus, and Web of Science. We included original research studies, systematic reviews, and meta-analyses that examined the impact of telehealth technologies on the management of patients with chronic diseases and were published in Polish or English between January 2020 and May 2026. Results. From the cited literature, it is clear that the use of telehealth has shown effectiveness in managing chronic disease. Although positive results can be observed in the short-term control of diseases such as hypertension, heart failure, diabetes, asthma, and chronic obstructive pulmonary disease, the effects of long-term management are unknown. Conclusions. This narrative review provides important insights regarding both the possible benefits and constraints of telehealth when managing chronic diseases. With the increasing use of telemedicine, it is vital to consider such difficulties and make sure that telehealth is accessible and efficient for all chronic patients.
- 8 July 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 61, 73300
Open AccessImpact of Telehealth on Chronic Disease Control: A Narrative Review
Background. With the continuous development of new technologies, especially digital technologies, the possibilities provided by telehealth continue to increase. Research shows that the use of telehealth tools can be successfully used for managing patients with chronic conditions. Aim. As the number of chronic conditions within the world’s population rises, their effect becomes evident in terms of lowering patients’ quality of life and life expectancy. Telehealth can be an effective solution to this growing problem. This review is intended to examine the state-of-the-art studies in relation to the effect of telehealth on chronic disorder management, focusing mainly on clinical outcomes, quality of life, and healthcare costs. Material and methods. We reviewed the available scientific literature in databases such as PubMed, Scopus, and Web of Science. We included original research studies, systematic reviews, and meta-analyses that examined the impact of telehealth technologies on the management of patients with chronic diseases and were published in Polish or English between January 2020 and May 2026. Results. From the cited literature, it is clear that the use of telehealth has shown effectiveness in managing chronic disease. Although positive results can be observed in the short-term control of diseases such as hypertension, heart failure, diabetes, asthma, and chronic obstructive pulmonary disease, the effects of long-term management are unknown. Conclusions. This narrative review provides important insights regarding both the possible benefits and constraints of telehealth when managing chronic diseases. With the increasing use of telemedicine, it is vital to consider such difficulties and make sure that telehealth is accessible and efficient for all chronic patients.
- Open Access
- 7 July 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 61, 73141
Polypharmacy in Elderly Patients: Clinical Risks, Drug Interactions and Strategies for Optimization – A Narrative Review
Background. Population aging and the growing prevalence of multimorbidity have led to an increasing number of older adults receiving multiple medications. Polypharmacy, commonly defined as the use of five or more medications, is associated with adverse drug reactions, drug interactions, functional decline, hospitalization, and mortality. Age-related physiological changes further increase susceptibility to medication-related harm. Aim. To review the epidemiology, clinical risks, drug interactions, and optimization strategies associated with polypharmacy in elderly patients. Material and methods. A narrative review of the literature was conducted using peer-reviewed articles, clinical guidelines, and consensus documents addressing polypharmacy in adults aged 65 years and older. Evidence related to epidemiology, pharmacological changes associated with aging, adverse drug events, assessment tools, potentially inappropriate medications, and optimization strategies was analyzed and synthesized narratively. Results. Polypharmacy is highly prevalent among older adults, especially those with multimorbidity and frailty. Age-related pharmacokinetic and pharmacodynamic changes increase the risk of adverse drug reactions and clinically significant drug interactions. Common consequences include falls, delirium, cognitive impairment, hospitalization, and increased mortality. Tools such as the Beers Criteria, STOPP/START criteria, and Medication Appropriateness Index help identify inappropriate prescribing. Key optimization strategies include comprehensive geriatric assessment, medication review, deprescribing, and interdisciplinary care. Conclusions. Polypharmacy remains a major challenge in geriatric care. Regular medication review, individualized treatment planning, and deprescribing interventions are essential to reduce medication-related harm and improve clinical outcomes in older adults.
- 7 July 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 61, 73141
Open AccessPolypharmacy in Elderly Patients: Clinical Risks, Drug Interactions and Strategies for Optimization – A Narrative Review
Background. Population aging and the growing prevalence of multimorbidity have led to an increasing number of older adults receiving multiple medications. Polypharmacy, commonly defined as the use of five or more medications, is associated with adverse drug reactions, drug interactions, functional decline, hospitalization, and mortality. Age-related physiological changes further increase susceptibility to medication-related harm. Aim. To review the epidemiology, clinical risks, drug interactions, and optimization strategies associated with polypharmacy in elderly patients. Material and methods. A narrative review of the literature was conducted using peer-reviewed articles, clinical guidelines, and consensus documents addressing polypharmacy in adults aged 65 years and older. Evidence related to epidemiology, pharmacological changes associated with aging, adverse drug events, assessment tools, potentially inappropriate medications, and optimization strategies was analyzed and synthesized narratively. Results. Polypharmacy is highly prevalent among older adults, especially those with multimorbidity and frailty. Age-related pharmacokinetic and pharmacodynamic changes increase the risk of adverse drug reactions and clinically significant drug interactions. Common consequences include falls, delirium, cognitive impairment, hospitalization, and increased mortality. Tools such as the Beers Criteria, STOPP/START criteria, and Medication Appropriateness Index help identify inappropriate prescribing. Key optimization strategies include comprehensive geriatric assessment, medication review, deprescribing, and interdisciplinary care. Conclusions. Polypharmacy remains a major challenge in geriatric care. Regular medication review, individualized treatment planning, and deprescribing interventions are essential to reduce medication-related harm and improve clinical outcomes in older adults.
- Open Access
- 7 July 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 61
The role of regular physical activity on the prevention and alleviation of gastroesophageal reflux disease and chronic constipation in patients with sedentary lifestyle
Background. Gastroesophageal reflux disease (GERD) and chronic constipation represent two of the most common functional gastrointestinal disorders, with elevated prevalence among sedentary individuals. Prolonged sitting acts as a risk factor by increasing intraabdominal pressure, compromising lower esophageal sphincter integrity, delaying colonic transit, impairing pelvic floor strength and inducing adverse shifts in gut microbiota. Aim. This study aimed to evaluate the impact of physical activity and sedentary behaviour on the development and management of GERD and chronic constipation Material and methods. This narrative review analyzed recent publications, predominantly from 2024–2026, identified through manual searches in PubMed, Embase, and Scopus using keywords related to physical activity, sedentary behaviour, GERD, and chronic constipation. Results. For chronic constipation, physical activity consistently accelerates intestinal transit, boosts colonic motility, promotes beneficial microbiota changes, and decreases risk by 30-34% at higher activity levels. Benefits are most pronounced with moderate aerobic modalities and are potentiated by concurrent dietary improvements. Conclusions. Moderate-intensity physical activity is an effective, safe, and low-cost strategy for preventing and managing GERD and chronic constipation. It improves reflux symptoms and bowel function, while high-intensity exercise may aggravate GERD. Reducing sedentary behavior is essential alongside increasing activity levels. Combined lifestyle interventions, including diet, provide the greatest benefit. A “movement-first” approach should be integrated into routine care. Further randomized controlled trials are required to establish optimal exercise prescriptions and clarify diet–activity interactions.
- 7 July 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 61
Open AccessThe role of regular physical activity on the prevention and alleviation of gastroesophageal reflux disease and chronic constipation in patients with sedentary lifestyle
Background. Gastroesophageal reflux disease (GERD) and chronic constipation represent two of the most common functional gastrointestinal disorders, with elevated prevalence among sedentary individuals. Prolonged sitting acts as a risk factor by increasing intraabdominal pressure, compromising lower esophageal sphincter integrity, delaying colonic transit, impairing pelvic floor strength and inducing adverse shifts in gut microbiota. Aim. This study aimed to evaluate the impact of physical activity and sedentary behaviour on the development and management of GERD and chronic constipation Material and methods. This narrative review analyzed recent publications, predominantly from 2024–2026, identified through manual searches in PubMed, Embase, and Scopus using keywords related to physical activity, sedentary behaviour, GERD, and chronic constipation. Results. For chronic constipation, physical activity consistently accelerates intestinal transit, boosts colonic motility, promotes beneficial microbiota changes, and decreases risk by 30-34% at higher activity levels. Benefits are most pronounced with moderate aerobic modalities and are potentiated by concurrent dietary improvements. Conclusions. Moderate-intensity physical activity is an effective, safe, and low-cost strategy for preventing and managing GERD and chronic constipation. It improves reflux symptoms and bowel function, while high-intensity exercise may aggravate GERD. Reducing sedentary behavior is essential alongside increasing activity levels. Combined lifestyle interventions, including diet, provide the greatest benefit. A “movement-first” approach should be integrated into routine care. Further randomized controlled trials are required to establish optimal exercise prescriptions and clarify diet–activity interactions.